What You Should Know:
- Health Transformation Alliance (HTA), a cooperative of nearly 60 of America’s largest employers, has partnered with Cognoa, a pediatric behavioral health company, to offer the company’s Canvas Dx diagnostic device for autism to all HTA Member organizations and their employees.
- HTA will offer its member organizations – some of the most influential and significant brands in the U.S. – the opportunity to add Canvas Dx to their benefit design.
Expanding Horizons By
Read More
Cognoa
Cognoa Appoints Former CMO, Dr. Sharief Taraman as CEO
What You Should Know:
- Cognoa, a pediatric behavioral health company appoints Dr. Sharief Taraman as Chief Executive Officer. Dr. Taraman previously served as Cognoa’s Chief Medical Officer and brings nearly two decades of clinical specialization in neurodevelopmental conditions, clinical informatics, and business acumen.
- Dr. Taraman served as the company’s Chief Medical Officer since 2017, leading clinical evidence generation and regulatory milestones of Canvas Dx and those resulting
Read More
Cognoa Awarded FDA Authorization For AI-Based Autism Diagnosis Aid
What You Should Know:
- Cognoa, a pediatric behavioral health company developing diagnostic and therapeutic solutions for children living with behavioral health conditions, has been granted FDA authorization to market the company’s first-of-its-kind, AI-based autism diagnosis aid – Canvas Dx.
- Canvas Dx is the first diagnosis aid designed to help physicians to diagnose autism spectrum disorder (ASD) in
Read More
Executive Hires: Walgreens Appoints New CEO, Cityblock Health, Innovaccer, Others
Walgreens appoints Rosalind (Roz) Brewer as the company’s Chief Executive Officer, effective on March 15, 2021. Brewer will also join the WBA Board of Directors upon assuming the role. She succeeds Stefano Pessina who, as previously announced, will transition to the role of Executive Chairman of the Board of WBA. Brewer, 58, will become the first Black woman to lead a Fortune 500 company.
Former Livongo President, Jennifer Schneider, has joined Cityblock Health’s Board of
Read More
Cerner Leadership Changes, Other Key Executives Hires
Cerner announced some leadership changes promoting long-time associates Travis Dalton to Chief Client & Services Officer and Dan Devers to Chief Legal Counsel. After long, respected, meaningful careers at Cerner, John Peterzalek and Randy Sims will be departing.
Cognoa, the leading pediatric behavioral health company developing diagnostic and therapeutic solutions for children living with autism and other behavioral health conditions appoints Eric B. Mosbrooker as
Read More
Cognoa Launches Pivotal Study of Diagnostic Aid for Autism
- Cognoa launches a pivotal study to demonstrate the effectiveness of its diagnostic aid for autism spectrum disorder (ASD).- The results of this pivotal study will be the basis for the submission to the FDA in 2020. - The Cognoa digital diagnostic aid has the potential to become the first cleared medical device to help diagnose autism intended to be used by pediatricians and primary care physicians.Cognoa, a Palo Alto, CA-based pediatric behavioral health company developing digital medicines,
Read More
Cognoa, EVERSANA Partner to Advance the Commercialization Standard for Prescription Digital Medicines
- Cognoa and EVERSANA form a partnership that will enable prescription, dispensation, and reimbursement of Cognoa’s behavioral health products.
- Cognoa is developing digital medicine solutions to change the standard of care in pediatric behavioral health to improve the lifelong outcomes for children.
- Cognoa selected EVERSANA, a fully integrated and independent commercial services platform, to develop and manage a go-to-market strategy that ensures comprehensive market
Read More
Cognoa Awarded FDA Breakthrough Designations for Diagnostic and Digital Therapeutic Devices for Autism
Cognoa, a digital health company focused on behavioral health for children, today announced FDA Breakthrough designations for it's first diagnostic and therapeutic devices to identify and treat autism. This is the foundation for its AI-based digital precision health to support the developmental and behavioral health of children, combining diagnostics and therapeutics into one platform. This signifies a big step in the company’s expansion into therapeutics.FDA Breakthrough Devices Program
Read More
Cognoa Lands $11.6M for Machine Learning App to Advance Diagnosis of Autism
Cognoa, a Palo Alto, CA-based digital health startup has raised $11.6 million in funding led by existing investor Morningside to advance earlier diagnosis of development delays in children. The company plans to utilize the funding to advance Cognoa's machine-learning-based technology; support additional clinical validation and the U.S. Food and Drug Administration (FDA) submissions and approvals process; and expand commercialization with employers, payers and clinicians. Cognoa has raised a
Read More
